Exelixis Inc (EXEL) News

Form 144 - Report of proposed sale of securities

Exelixis to Webcast Fireside Chats as Part of Investor Conferences in December

-- Presentations to be webcast on www.exelixis.com -- Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in...

Form 4 - Statement of changes in beneficial ownership of securities

Exelixis Provides Regulatory Update Related to Supplemental New Drug Application for Cabozantinib (CABOMETYX®) for the Treatment of Patients with Previously Treated Advanced Neuroendocrine Tumors

Exelixis, Inc. (Nasdaq: EXEL) today announced that the U.S. Food and Drug Administration (FDA) has notified the company that the supplemental New...

Form 144 - Report of proposed sale of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

Form 4 - Statement of changes in beneficial ownership of securities

Exelixis to Webcast Fireside Chats as Part of Investor Conferences in November

- Presentations to be webcast on www.exelixis.com - Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in...